BioMarin Pharmaceutical Inc. Common Stock Earnings Dividend

BioMarin Pharmaceutical Inc. Common Stock’s revenue jumped 2.83% since last year same period to $766.21Mn in the Q1 2026. On a quarterly growth basis, BioMarin Pharmaceutical Inc. Common Stock has generated -12.39% fall in its revenue since last 3-months.

BioMarin Pharmaceutical Inc. Common Stock’s net profit fell -43.17% since last year same period to $105.53Mn in the Q1 2026. On a quarterly growth basis, BioMarin Pharmaceutical Inc. Common Stock has generated 326.58% jump in its net profits since last 3-months.

BioMarin Pharmaceutical Inc. Common Stock’s net profit margin fell -44.73% since last year same period to 13.77% in the Q1 2026. On a quarterly growth basis, BioMarin Pharmaceutical Inc. Common Stock has generated 358.63% jump in its net profit margins since last 3-months.

BioMarin Pharmaceutical Inc. Common Stock’s price-to-earnings ratio after this Q1 2026 earnings stands at 37.68.

BioMarin Pharmaceutical Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.96 - a 5.49% jump from last quarter’s estimates.

BioMarin Pharmaceutical Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 0.96.

BioMarin Pharmaceutical Inc. Common Stock’s earning per share (EPS) fell -32.74% since last year same period to 0.76 in the Q1 2026. This indicates that the BioMarin Pharmaceutical Inc. Common Stock has generated -32.74% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. BioMarin Pharmaceutical Inc. Common Stock’s return on assets (ROA) stands at 0.04.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. BioMarin Pharmaceutical Inc. Common Stock’s return on equity (ROE) stands at 0.04.